公开(公告)号：US20240191252A1

公开(公告)日：2024-06-13

申请号：US18286103

申请日：2022-04-07

申请人： IMMVIRA BIOPHARMACEUTICALS CO., LIMITED

发明人： Xiaoqing CHEN ,  Yuanyuan LIU ,  Ziwen LIU ,  Tianyi DENG ,  Grace Guoying ZHOU

IPC分类号： C12N15/86 ,  A61K35/763 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C07K14/52 ,  C07K14/54 ,  C07K14/82 ,  C07K16/28

CPC分类号： C12N15/86 ,  A61K35/763 ,  A61K39/001106 ,  A61K39/001112 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464412 ,  A61P35/00 ,  C07K14/4748 ,  C07K14/521 ,  C07K14/5434 ,  C07K14/82 ,  C07K16/2818 ,  A61K2039/5256 ,  A61K2239/46 ,  A61K2239/57 ,  A61K2239/58 ,  C12N2710/16632 ,  C12N2710/16643

摘要： Disclosed is a genetically modified oncolytic herpes simplex virus (oHISV) encoding a truncated nonsignaling variant of at least one tumor associated/specific antigen, and at least one chemokine. The expression of the truncated nonsignaling variant and the chemokine is under the control of an immediate-early gene promoter of HSV, and the truncated nonsignaling variant is expressed and presented on a tumor cell surface as a biomarker upon replication of the oHSV in the tumor cell, and the chemokine is expressed and released to induce chemotaxis of an immune cell towards the tumor cell. The genetically modified oHSV can be used in combination with CAR-T, ADC, and/or BiTE therapies.